JOSEPH LABRICCIOSA: Open Payments
NPI 1053315523 · BROOMALL, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,327 in 149 payments from 29 companies in 2025. Trend: 2023 $3,147 · 2024 $3,264 · 2025 $3,327
Food & beverage: $3,327
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $486 |
| Axsome Therapeutics, Inc. | 13 | $381 |
| PFIZER INC. | 14 | $340 |
| AstraZeneca Pharmaceuticals LP | 9 | $205 |
| GlaxoSmithKline, LLC. | 8 | $166 |
| Astellas Pharma US Inc | 4 | $113 |
| Novo Nordisk Inc | 5 | $110 |
| Aimmune Therapeutics, Inc. | 4 | $103 |
| Otsuka America Pharmaceutical, Inc. | 6 | $102 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $98 |
Products named: NURTEC ODT, Auvelity, REXULTI, TRELEGY ELLIPTA, FARXIGA, VRAYLAR, LINZESS, Sunosi.
Industry payments across PA — which companies pay providers there.
